Review
Copyright ©The Author(s) 2023.
World J Hepatol. Oct 27, 2023; 15(10): 1109-1126
Published online Oct 27, 2023. doi: 10.4254/wjh.v15.i10.1109
Table 5 Drugs, their mechanism of action, dosage and side effects
Name of drug
Mechanism of action
       Dose
When to start
Side effects
D-penicillamineInduces cuprieuresis, induces hepatic metallothionine synthesis, reduces fibrosis (by preventing collagen formation)20 mg/kg/d (maximum induction dose of 1500 mg/d and maintenance dose of 1000 mg/d), to be taken 1 h before or 2 h after meal, storage at room temperatureChelator of choice in all hepatic phenotypeEarly (1-3 wk): Fever, rash, arthralgia, cytopenia, proteinuria; Late: (1) Skin: degenerative dermatoses elastosis perforans serpingosa, cutis laxa, pseudoxanthoma elasticum, bullous dermatoses, psoriasiform dermatoses, lichen planus, seborrheic dermatitis alopecia, aphthous ulcerations, hair loss; (2) Connective tissue disorders: Lupus like syndrome, arthralgia, Rheumatoid arthritis, polymyositis; (3) Renal: proteinuria, hematuria, glomerulonephritis, nephrotic syndrome, renal vasculitis, Goodpasture’s syndrome; (4) Nervous system: Paradoxical neurological worsening, neuropathies, myasthenia, hearing abnormalities, serous retinitis; (5) Gastrointestinal: Nausea, vomiting, diarrhea, elevated transaminases, cholestasis, hepatic siderosis; (6) Respiratory: Pneumonitis, pulmonary fibrosis, pleural effusion; (7) Hematological: Cytopenia, agranulocytosis, aplastic anemia, hemolytic anemia; and (8) Others: Immunoglobulin deficiency, breast enlargement, pyridoxine deficiency
TrientineInduces cuprieuresis, induces hepatic metallothionine synthesis20 mg/kg/d (maximum induction dose of 1500 mg/d and maintenance dose of 1000 mg/d), to be taken 1 h before or 2 h after meal, storage at 20-80 temperatureIndicated if intolerant to D-penicillamineParadoxical neurological worsening (10%-50%), sideroblastic anemia, bone marrow suppression, gastritis, skin rash, arthralgia, myalgia, hirsutism
ZincInduces intestinal synthesis of metallothioneins, prevents copper absorption25 mg thrice daily (weight < 50 kg), 50 mg thrice daily (weight > 50 kg), taken in empty stomachMaintenance phase of symptomatic hepatic WD; First-line induction treatment in selected patient subgroups (neurologic WD, intolerant to chelators, pre-symptomatic patients)Gastric irritation (30%-40%)
Ammonium Tetra-thiomolybdateForms complexes with copper in blood, binds the copper present in foodNeurological WDNeurological dysfunction (rare), hepatotoxicity, bone marrow suppression